Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death
- 21 February 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (8), 771-783
- https://doi.org/10.1056/nejmoa0707571
Abstract
Aprotinin (Trasylol) is used to mitigate bleeding during coronary-artery bypass grafting (CABG). Accumulating evidence suggests that this practice increases mortality.Keywords
This publication has 32 references indexed in Scilit:
- Public Reporting and Pay for Performance in Hospital Quality ImprovementNew England Journal of Medicine, 2007
- Simultaneous assessment of short‐term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysisArthritis & Rheumatism, 2006
- Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental VariableEpidemiology, 2006
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- The efficacy and safety of ɛ‐aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysisAlimentary Pharmacology & Therapeutics, 2005
- An application of propensity score matching using claims dataPharmacoepidemiology and Drug Safety, 2005
- Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trialsThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet TherapyClinical Pharmacokinetics, 2004
- Identification of Causal Effects Using Instrumental VariablesJournal of the American Statistical Association, 1996
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983